You are viewing: UK Oral Proteins & Peptides Market analysis

The UK Oral Proteins & Peptides Market was valued at $320.8 Million in 2025 and projected to reach to $884.5 Million by 2030, representing a compound annual growth rate of 22.5%. The UK oral proteins & peptides market is poised for substantial expansion through 2030, supported by technological advances in formulation science and increasing NHS adoption of peptide therapeutics.

UK Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Oral Proteins & Peptides Market Trends and Insights

  • The UK market is driven by increasing demand for non-invasive drug delivery solutions and rising prevalence of chronic diseases requiring peptide-based therapeutics.
  • The UK's advanced healthcare infrastructure and strong regulatory framework position it as a key hub for oral peptide innovation in Europe. The UK market benefits from substantial investment in biotechnology and pharmaceutical R&D, with numerous companies developing next-generation oral formulations.
  • Between 2025 and 2030, the UK is expected to see accelerated adoption of oral peptide therapies across diabetes management, gastrointestinal disorders, and metabolic conditions.
  • The UK's aging population and healthcare system's focus on patient-centric treatment options further support market expansion during this forecast period..

Key Market Statistics

  • CAGR (2025-2030) 22.5% CAGR
  • Market Size, 2025 ~USD 320.8 Million
  • Forecast, 2030 ~USD 884.5 Million
  • Country UK

UK Oral Proteins & Peptides Market Overview

Market Valuation Growth :

The UK oral proteins & peptides market is valued at $320.8 million in 2025, with projections reaching $884.5 million by 2030, representing a robust 22.5% CAGR over the forecast period.

Non-Invasive Drug Delivery Demand :

UK healthcare providers and patients are increasingly adopting oral peptide formulations as alternatives to injectable therapies, driven by improved patient compliance and quality of life considerations.

Chronic Disease Prevalence :

Rising incidence of diabetes, obesity, and gastrointestinal disorders in the UK population is fueling demand for peptide-based therapeutics that address these conditions through oral administration.

Regulatory & Infrastructure Advantages :

The UK's advanced healthcare infrastructure, MHRA regulatory framework, and strong pharmaceutical R&D ecosystem position it as a leading market for oral peptide innovation and commercialization.

UK Oral Proteins & Peptides Market Dynamics

  • Pharmaceutical companies are investing heavily in UK-based research facilities to develop next-generation oral delivery systems that overcome bioavailability challenges.
  • The market will benefit from growing patient preference for oral medications, enhanced reimbursement policies, and collaboration between UK academic institutions and industry players.
  • Additionally, the post-Brexit regulatory environment has streamlined approval pathways for innovative peptide drugs, attracting both domestic and international manufacturers to establish UK operations..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • The UK oral proteins & peptides market will grow from $320.8M (2025) to $884.5M (2030), representing a 22.5% CAGR.
    • The UK's advanced regulatory environment and biotech ecosystem accelerate development and commercialization of oral peptide therapies.
    • The UK market is driven by rising chronic disease prevalence and patient demand for non-invasive delivery alternatives.
    • The UK's healthcare system prioritizes innovative treatments, positioning the country as a leader in oral peptide adoption across Europe.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    UK Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS84.7148.4193.9237.5290.8357.6441.4547.123.1
    HOSPITALS & SPECIALTY CLINICS22.7395060.172.186.9105.2127.720.6
    LONG-TERM CARE FACILITIES3459.276.893.4113.7138.8170.2209.622.2
    TOTAL141.5246.7320.8391476.6583.3716.8884.522.5

    Target Audience

    • Pharmaceutical Manufacturers : UK and international pharma companies need detailed market data to evaluate UK market opportunity, plan product launches, allocate R&D resources, and develop go-to-market strategies for oral peptide therapeutics.
    • Biotech & Contract Research Organizations : UK-based biotech firms and CROs require market intelligence to identify partnership opportunities, secure funding, and position their oral peptide formulation technologies within the growing UK market.
    • Healthcare Investors & Private Equity : Investment firms evaluating UK healthcare opportunities need comprehensive market analysis to assess portfolio companies, identify acquisition targets, and evaluate return potential in the oral peptides sector.
    • NHS & Healthcare Procurement : NHS trusts and healthcare procurement teams use market data to understand available oral peptide options, evaluate cost-effectiveness, and make informed decisions on therapeutic adoption and budgeting.
    • Medical Device & Delivery System Companies : Manufacturers of oral delivery technologies and formulation excipients need UK-specific market insights to identify customer segments, develop targeted solutions, and forecast demand for their enabling technologies.

    Key Companies in the UK Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise UK market valuation ($320.8M in 2025) and verified 5-year forecast data to support investment decisions, business planning, and competitive positioning in the rapidly expanding oral peptides sector.
    • UK-Specific Regulatory Intelligence : Access detailed insights into MHRA approval pathways, post-Brexit regulatory changes, and NHS reimbursement trends specific to oral peptide products in the UK market.
    • Competitive Landscape Analysis : Identify key UK-based and international players, their market share, product pipelines, and strategic initiatives to benchmark your organization's position and identify partnership opportunities.
    • Patient & Healthcare Provider Insights : Understand UK patient preferences for oral over injectable peptide therapies, NHS adoption rates, and healthcare provider perspectives to inform product development and commercialization strategies.
    • Growth Driver Identification : Leverage comprehensive analysis of UK-specific growth catalysts including chronic disease prevalence, technological innovations, and healthcare infrastructure advantages to prioritize market entry or expansion.

    Frequently asked questions

    What is the current size of the UK oral proteins & peptides market?

    The UK oral proteins & peptides market is valued at $320.8 million in 2025 and is expected to reach $884.5 million by 2030.

    What is the projected growth rate for the UK market?

    The UK oral proteins & peptides market is projected to grow at a compound annual growth rate (CAGR) of 22.5% from 2025 to 2030.

    What factors are driving growth in the UK market?

    Key drivers include increasing demand for non-invasive drug delivery, rising chronic disease prevalence, strong biotech R&D investment, and the UK's advanced healthcare infrastructure.

    Which therapeutic areas are leading the UK market?

    The UK market is seeing strong growth in diabetes management, gastrointestinal disorders, and metabolic conditions driven by oral peptide therapies.

    How does the UK market compare to other European markets?

    The UK's advanced regulatory framework, robust biotech ecosystem, and healthcare system focus on innovation position it as a leading market for oral peptide adoption in Europe.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status